Boston Scientific Corp Bags FDA Approval for Spinal Cord Stimulator Systems for Treatment of Non-Surgical Back Pain
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific Corporation (NYSE:BSX) received FDA approval for an expanded indication of its WaveWriter SCS Systems to treat chronic low back and leg pain in individuals without prior back surgery, known as non-surgical back pain (NSBP).

February 06, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific Corporation received FDA approval for expanded use of its WaveWriter SCS Systems for non-surgical back pain treatment.
FDA approvals are critical milestones for medical device companies, often leading to increased product adoption and market expansion. This approval allows Boston Scientific to target a broader patient population, potentially boosting sales and enhancing its market position in pain management solutions. Given the prevalence of chronic low back and leg pain, and the limitation of treatment options for patients without prior surgery, this approval could significantly impact Boston Scientific's revenue and market share in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100